After three years of intense restrictions, China has finally opened its borders. But one overarching question remains: Is China investable again?
According to the top research providers, the short answer is yes.
“Our outlook for China entering the new year is positive,” said Peng Wensheng, head of the research department at China International Capital Corp. “China’s macroeconomic policies have supported growth, and recent changes to Covid-19 and property sector policies will likely boost economic activity and corporate earnings in the coming quarters.”
In the All-China Sales Team, Huatai outpaced CICC to take the No. 1 spot. CICC ended up at No. 2, where it was followed by UBS and JPMorgan in third and fourth place, respectively. BofA rose two spots to place fifth.
To select the members of Institutional Investor’s eleventh annual All-China Sales Team, we invited participants in the 2022 All-China Research Team survey to rate firms across six attributes. We received responses from over 570 buy-side analysts and money managers at more than 360 firms.
A numerical score was produced by weighting each vote by the respondent’s Chinese equity assets under management and the average rating awarded. Using those scores, ranks were determined.
In order to portray the difference in perspective between domestic and international investors, we divided respondents according to their location to produce two additional rankings: a mainland view and an international view.
The names of those surveyed are kept confidential to ensure their continuing cooperation. Voters must meet eligibility requirements, and winners must achieve a minimum vote count. All ballots are subject to review by our Research Operations Group.
To view the full rankings, subscribe now. Already a subscriber? login.